Introduction
Duchenne/Becker muscular dystrophies (D/BMD) are the most frequent muscle diseases in children caused by mutations arising in the gene encoding dystrophin, a cytoskeletal protein. It is estimated to affect 1 in 3,500 newborn males worldwide (Emery, 1991) . About 30-35% cases of D/BMD are assumed to result from microdeletions, microinsertions or substitutions of one or more nucleotide(s). Several independent studies have reported small mutations in the dystrophin gene (Kiliman et al., 1992; Nigro et al., 1992 Nigro et al., , 1994 Roberts et al., 1992; Tuffery et al., 1993 Tuffery et al., , 1995 Tuffery et al., , 1996 Kneppers et al., 1995; Sitnik et al., 1997; Eranslan et al., 1999; Wibawa et al., 2000) . These are randomly distributed throughout the dystrophin gene (http://www.dmd.nl).
Till date, 370 sequence variations have been identified in the human dystrophin gene and 177 mutations were found to be responsible for the disease (http:// www.dmd.nl). Most of the point mutations lead to premature translational termination due to nonsense (34%), frameshift (33%), splice site (29%) and missense (4%) mutations in the dystrophin gene (Rininsland and Reiss, 1994; Roberts et al., 1994; Barbieri et al., 1995; Gardner et al., 1995; Prior et al., 1995; Winnard et al., 1995) .
In the course of point mutation analysis in D/BMD patients, several sequence variations have been reported which do not cause any change in the gene size but cause minor substitutions. It is difficult to predict whether the observed change is a mutation or a rare polymorphism (Tuffery et al., 1992; Saad et al., 1994 Saad et al., , 1997 Saad et al., , 1998 Todorova and Daneili, 1997; Chen et al., 1998) .
In our laboratory more than 400 D/BMD patients have been registered so far. In about one third of patients, no detectable deletion was observed using m-PCR and Southern blotting, and was therefore presumed to have point mutations (Singh et al., 1997) . In order to look for point mutations in the dystrophin gene, six exons of the dystrophin gene (5 proximal and 1 central regions) were screened by using Single Strand Conformation Analysis (SSCA) and Heteroduplex Analysis (HA) in 50 unrelated non-deletional D/BMD patients. Bands shifted in SSCA and HA were further analyzed by sequencing.
Materials and Methods

Patients
A total of 50 clinically confirmed unrelated non-deletional D/BMD patients (38 DMD and 12 BMD) from North India were subjected to point mutation analysis. Clinical diagnosis was based on EMG, Gower's sign, Pradhan's sign and calf hypertrophy (Sinha et al., 1992; Pradhan and Mittal, 1995) . The deletion analysis was performed by m-PCR using 25 pairs of primers (Pm, 3, 4, 6, 8, 12, 13, 17, 20, 21, 22, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, and 60) of the dystrophin gene (Chamberlain et al., 1988; Beggs et al., 1990; Sinha et al., 1992; Singh et al., 1997) . Mutation analysis was carried out using six exonic regions with flanking intronic sequences (Exons 4, 6, 8, 12, 17 and 44) in two triplex PCRs (Exons 6, 8, 17 and Exons 4, 12, 44) .
Single Strand Conformation Analysis (SSCA)
The selected exons were amplified in two m-PCR with DNA samples of all 50 patients and two normal male individuals as controls. Five µl PCR product (80-100 ng) of each patient and normal male individual were diluted with equal volumes of denaturing buffer (98% formamide, 10 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol), denatured at 95 o C and loaded on a 0.5 X MDE TM (Mutation detection enhancement) gel (20×40 cm, 0.5 mm thick) prepared according to FMC Bioproducts protocol. The samples were run at a constant power of 6 W for 10 h at room temp in 0.6 X TBE with or without 5% glycerol. The bands were visualized by silver staining.
Heteroduplex Analysis (HA)
The selected exons were amplified in two m-PCR with DNA samples of the patients and two normal male individuals as controls. Five µl of PCR product (80-100 ng) of each patient was mixed with an equal amount of control product, denatured at 95 o C for 5 min and reannealed at 37 o C for 1 h. Five µl (30-35 ng) of reannealed fragments were mixed with double dye (30% sucrose, 0.05% bromophenol blue and 0.05% xylene cyanol) and loaded onto a 1X MDE gel (20×40 cm, 1 mm thick). Electrophoresis was carried out at a constant voltage of 600V for 8 h at room temperature in 0.6 X TBE and the bands were visualized by silver staining.
DNA Sequencing
The PCR products were purified from low melting point (LMP) agarose and subjected to manual and automated sequencing. Manual sequencing of the purified PCR product was carried out using di-deoxy thermosequenase radiolabelled terminator cycle sequencing kit (Amersham Life Sciences). The sequencing gel was electrophoresed at 1700 V for 4 h, fixed for 10 min in 10% acetic acid (v/v) containing 10% methanol (v/v), vacuum dried at 80 o C for one hr and exposed to X-ray film (XOmat TM , XK-5) for 24-36 h at -80 o C. The autoradiograms were developed and read carefully.
Automated sequencing (Applied Biosystems model 373A) of the purified PCR products was carried out using FS-Dye termination cycle sequencing ready reaction kit (Perkin Elmer, USA). At the completion of the reaction, the volume of reaction mix was raised to 100 µl and phenolized once with phenol: chloroform (68:14). The aqueous layer was precipitated with ethanol and the pellet was washed with 70% ethanol and dried. It was then dissolved in 5 µl of formamide loading buffer, denatured and loaded onto a sequencing gel. Before loading the samples, the background fluorescence was measured and scan area was cleaned to get a uniform base line for all the sample lines. The samples were electrophoresed for 16 h at 40 W. The sequence was obtained as an electropherogram. The nucleotide sequence so obtained was analyzed using PC-Gene software rel. 17.0 (Intelligenetics, USA). The BLAST program was used for analysis of nucleotide sequences.
Results
Out of 50 unrelated D/BMD patients analysed for point mutation detection, the electrophoretic mobility shift was observed in three patients: one by SSCP and two by HA. All three changes were observed in exon 17 (Figures 1, 2) . Sequencing of the amplified PCR products confirmed the nucleotide alteration in all the three patients (Figures 3-5) . SSCA showed a band shift only in exon 17 in one of the patients, MD-138 (BMD) (Figure 1 ). In the remaining 49 patients, no band shift was observed in any of the exons analysed. The manual dideoxy sequencing of exon 17 showed a substitution in the intronic region (-37 g → t) in MD-138 when compared to the normal male control (Figure 3 ).
The heteroduplex formation was observed in exon 17 in two patients, MD-28 and MD-70 (one DMD and one BMD respectively) (Figures 2). Automated DNA sequencing of exon 17 using fluorescent dideoxy dye termination showed a substitution in the intronic region (-37 g → t) in the BMD patient, MD-70 (Figure 4) . In case of MD-28, HA was further carried out in the DNA samples of mother, father and unaffected brother. In the mother, a heteroduplex formation was observed as in the proband (Figure 2 ). Automated DNA sequencing showed a substitution (transition) in the exonic region at 68 th nucleotide position of exon 17 (C2268T) of the dystrophin gene. Sequencing the PCR products of father, unaffected son, mother and normal male control revealed that the father and son had no change in the sequence but the mother was heterozygous for the change (Figure 5 ). In the remaining patients, no heteroduplex formation was observed in the other exons. The results of BLAST searches are shown in Figure 6 .
Discussion
Several independent investigators have used different methods to search for point mutations in the dystrophin gene in 30% of D/BMD patients. SSCA (Orita et al., 1989; Glavac and Dean, 1993) and HA (Glavac and Dean, 1995) are mutation detection techniques that rely on detecting changes in the physical properties of DNA caused by the presence of sequence changes. These methods have shown an efficiency of 7-27% depending on the conditions and exons analysed (Soto and Sukumar, 1992; White et al., 1992; Kneppers et al., 1995; Eranslan et al., 1999) . Prior et al. (1995) screened around 80% of the dystrophin coding sequences for small mutations by using HA in 158 patients and identified mutations in 29 of them. They concluded that in many of the DMD and majority of BMD, small mutations lie in the non-coding regions of the gene. Eranslan et al. (1999) screened 18 deletion-prone exons (25.5% of the coding region) of the dystrophin gene by using non-isotopic multiplex SSCA in 56 unrelated non-deletional D/BMD patients. They In the present study, sequencing showed a nucleotide substitution of G to T in the intronic region (2201-37G/ T) in two patients (MD-138 and MD-70) and a nucleotide substitution in the exon 17 (C2268T) in one (MD-28). The observed intronic nucleotide change in the dystrophin gene has been reported earlier by many independent investigators (Kiliman et al., 1992; Tuffery et al., 1992; Nigro et al., 1994; Prior et al., 1995; Sitnik et al., 1997) . They have observed this not only in D/ BMD patients but also in normal individuals, thereby constituting a rare polymorphism. The possibility of it being involved in the pathogenesis of the disease is ruled out since it is away from the splice site.
In MD-28 the nucleotide substitution (C2268T) in the exon 17 resulted in an amino acid alteration from threonine to methionine at the 687th position of the dystrophin protein. The sequence homology analysis using BLAST depicted that the substituted nucleotide is present in chicken and murine dystrophin gene. Therefore, this change does not appear to be conserved across species. Thus, it suggests that this change may not be responsible for the disease but appears to be a polymorphism. In the family of MD-28, the mother was found to be heterozygous for the C2268T nucleotide substitution. The sequence analysis showed that the substituted nucleotide was inherited with the disease phenotype.
